Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away [Seeking Alpha]
IDEAYA Biosciences, Inc. (IDYA)
Last ideaya biosciences, inc. earnings: 3/24 06:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
IDYA's darovasertib shows promising Phase 2 results and multiple pivotal studies, with a potential $500M+ peak revenue opportunity and a strong partnership with Servier. The pipeline includes collaborations with major pharma and several near-term catalysts, suggesting IDYA's current $3.1B valuation undervalues its broader portfolio. I rate IDYA a Buy, citing strong leadership, cash position, and pipeline potential, but caution on clinical risks and recommend vigilance around upcoming pivotal data. SvetaZi/iStock via Getty Images Investment Overview Ideaya Biosciences, Inc. IDYA ) is a "precision medicine oncology" company that IPO'd in May 2019, raising $57.5m via the issuance of 5.75m shares at $10 per share. Stock is valued at $35 per share More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market,
Show less
Read more
Impact Snapshot
Event Time:
IDYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IDYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IDYA alerts
High impacting IDEAYA Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IDYA
News
- IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance [Yahoo! Finance]Yahoo! Finance
- IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND ClearanceBusiness Wire
- IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND ClearanceBusiness Wire
- IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor TypesPR Newswire
- A Closer Look at IDEAYA Biosciences (IDYA) Valuation as Investor Optimism Builds [Yahoo! Finance]Yahoo! Finance
IDYA
Earnings
- 11/4/25 - Beat
IDYA
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- 11/4/25 - Form 8-K
- IDYA's page on the SEC website